% IMPORTANT: The following is UTF-8 encoded.  This means that in the presence
% of non-ASCII characters, it will not work with BibTeX 0.99 or older.
% Instead, you should use an up-to-date BibTeX implementation like “bibtex8” or
% “biber”.

@ARTICLE{Kampers:299783,
      author       = {L. F. C. Kampers and D. Metselaar$^*$ and M. Vinci and F.
                      Scirocchi and S. Veldhuijzen van Zanten and M. Eyrich and V.
                      Biassoni and E. Hulleman and M. Karremann and W. Stücker
                      and S. W. Van Gool},
      title        = {{T}he {C}omplexity of {M}alignant {G}lioma {T}reatment.},
      journal      = {Cancers},
      volume       = {17},
      number       = {5},
      issn         = {2072-6694},
      address      = {Basel},
      publisher    = {MDPI},
      reportid     = {DKFZ-2025-00538},
      pages        = {879},
      year         = {2025},
      abstract     = {Malignant glioma is a highly aggressive, therapeutically
                      non-responsive, and deadly disease with a unique tumor
                      microenvironment (TME). Of the 14 currently recognized and
                      described cancer hallmarks, five are especially implicated
                      in malignant glioma and targetable with repurposed drugs:
                      cancer stem-like cells, in general, and glioma stem-like
                      cells in particular (GSCs), vascularization and hypoxia,
                      metabolic reprogramming, tumor-promoting inflammation and
                      sustained proliferative signaling. Each hallmark drives
                      malignant glioma development, both individually and through
                      interactions with other hallmarks, in which the TME plays a
                      critical role. To combat the aggressive malignant glioma
                      spatio-temporal heterogeneity driven by TME interactions,
                      and to overcome its therapeutic challenges, a combined
                      treatment strategy including anticancer therapies,
                      repurposed drugs and multimodal immunotherapy should be the
                      aim for future treatment approaches.},
      subtyp        = {Review Article},
      keywords     = {immunotherapy (Other) / malignant glioma (Other) / tumor
                      microenvironment (Other)},
      cin          = {B062 / HD01},
      ddc          = {610},
      cid          = {I:(DE-He78)B062-20160331 / I:(DE-He78)HD01-20160331},
      pnm          = {312 - Funktionelle und strukturelle Genomforschung
                      (POF4-312)},
      pid          = {G:(DE-HGF)POF4-312},
      typ          = {PUB:(DE-HGF)16},
      pubmed       = {pmid:40075726},
      doi          = {10.3390/cancers17050879},
      url          = {https://inrepo02.dkfz.de/record/299783},
}